New Age Alpha Advisors LLC Purchases New Position in United Therapeutics Co. (NASDAQ:UTHR)

New Age Alpha Advisors LLC acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 4,637 shares of the biotechnology company’s stock, valued at approximately $1,636,000.

Other hedge funds also recently made changes to their positions in the company. Cerity Partners LLC increased its position in United Therapeutics by 82.1% during the third quarter. Cerity Partners LLC now owns 8,886 shares of the biotechnology company’s stock worth $3,184,000 after buying an additional 4,005 shares during the period. FMR LLC raised its position in United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after purchasing an additional 314,004 shares during the last quarter. Brooklyn Investment Group purchased a new position in United Therapeutics during the 3rd quarter worth $33,000. Townsquare Capital LLC acquired a new position in United Therapeutics in the third quarter valued at $426,000. Finally, CreativeOne Wealth LLC purchased a new stake in shares of United Therapeutics in the third quarter valued at about $215,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on UTHR. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $388.25.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $940,373.07. This represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now directly owns 8,480 shares of the company’s stock, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,500 shares of company stock valued at $26,134,500 in the last ninety days. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $306.97 on Monday. United Therapeutics Co. has a fifty-two week low of $221.53 and a fifty-two week high of $417.82. The firm has a market capitalization of $13.79 billion, a price-to-earnings ratio of 13.48, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The stock’s fifty day moving average is $340.06 and its two-hundred day moving average is $355.85.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the company earned $4.36 EPS. As a group, sell-side analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.